Headline AstraZeneca is star stock of 2008 while Merck loses shine
Source EP Vantage
Company AstraZeneca, Abbott Laboratories, Amgen, Bayer, Bristol-Myers Squibb, Eli Lilly, Genentech, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Wyeth 
Date January 09, 2009
 

An analysis of last year’s share price performances among the world’s biggest drug makers reveals that the league table largely reversed itself compared to 2007.

AstraZeneca, which struggled to generate many positive headlines in 2007, put in an impressive performance, recovering all the losses of the previous year and adding some for good measure. It ended up by far the best performing major healthcare stock in 2008, up 30%. At the other end of the scale, Merck & Co demonstrated how swiftly things can take a turn for the worse and delivered a staggering $58bn plunge in its market cap as the company almost halved in value across the year (see table below).
 

This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
EP Vantage SM ©2010 EP Vantage Ltd